Seven-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one reduces atherogenic index and Nrf2 and GPx gene expressions in hyperlipidemic rats

Prasetyastuti¹*, Rahmah Dara Ayunda², Sunarti¹
¹Faculty of Medicine, Public Health and Nursing, ²Biomedical Science, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

*For correspondence: Email: prasetyastuti.djati@gmail.com; Tel: +62-81227882379

Sent for review: 5 December 2018 Revised accepted: 20 May 2019

Abstract

Purpose: To investigate the effect of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one isolated from mahogany (Swietenia macrophylla King) seeds on atherogenic index, expressions of nuclear factor erythroid 2-related factor 2 (Nrf2) and expression of the glutathione peroxidase (GPx) genes in hyperlipidemic rats.

Methods: A total of 25 rats male aged 8 weeks and weighing an average of 200 g were used. They were divided into five groups as follows: (I) normal (N), (II) hyperlipidemic (HL), (III) hyperlipidemic rats treated with simvastatin (HL+SV), (IV and V) hyperlipidemic rats treated with 30 or 90 mg, respectively, of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one per 200 g body weight per day for 4 weeks. Atherogenic index (AI) was calculated from the levels of triglyceride (TG) and high-density lipoprotein (HDL) while Nrf2 and GPx gene expressions were determined by quantitative real-time polymerase chain reaction (qRT-PCR).

Results: Two different doses of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one in hyperlipidemic rats significantly reduced their atherogenic index (p < 0.05). Nrf2 and GPx expression levels were lower than (p > 0.05) those of hyperlipidemic group.

Conclusion: Seven-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one reduces the atherogenic index and expression levels of Nrf2 and GPx genes in hyperlipidemic rats. Thus, this compound has potential as an antihyperlipidemic agent.

Keywords: Hyperlipidemia, Oxidative stress, Nrf2, GPx, Gene expression

INTRODUCTION

Hyperlipidemia, a form of dyslipidemia, is a lipid metabolism disorder characterized by increased levels of cholesterol and/or triglycerides. Hyperlipidemia is caused by many factors, including an unhealthy lifestyle, low physical activity, and a high-fat diet [1].

Oxidative stress causes translocation of the nuclear factor erythroid 2-related factor 2 (Nrf2) from the cytoplasm to the nucleus, where it combines with the antioxidant-responsive...
Oxidative stress can be prevented by endogenous and exogenous antioxidants. Endogenous antioxidants protect cells from damage caused by oxidative stress. In hyperlipidemia, endogenous antioxidants are not sufficient to prevent cell damage. Therefore, exogenous antioxidants are needed to protect cells from oxidative stress-related diseases.

Many studies have reported that flavonoid compounds reduce oxidative stress. A previous study found that 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one isolated from mahogany seeds (*Swietenia macrophylla* King) influences the expression of some genes involved in carbohydrate metabolism in a rat Type 2 diabetes mellitus (T2DM) model [6]. This study aimed to evaluate the effects of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one flavonoid groups on the atherogenic index and expression of *Nrf2* and *GPx* genes in hyperlipidemic rats.

**EXPERIMENTAL**

**Animals**

Twenty-five male rats (*Rattus norvegicus*), aged 8 weeks old, with an average weight of 200g, were obtained from the Center for Food and Nutrition Studies, Universitas Gadjah Mada, Yogyakarta, Indonesia. The rats were housed in individual cages and acclimatized to laboratory conditions (22–25°C) and a 12-h daylight cycle for 7 days with free access to food and water. The standard diet was AIN 93 M consisting of (g/kg): casein 24 %, DL-methionine 0.30 %, corn starch 61%, vitamin mixture 1 %, mineral mixture 3.5 %, and choline chloride 0.2 %, with 5 % alpha cells and 5 % corn oil. This study was approved by the Health and Medical Research Ethics Committee of the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia (approval no.KE/FK/0729/EC/2018) and was conducted in accordance with the guidelines of Declaration of Helsinki issued in 1964 and amended in 1996 [7].

**Experimental design**

Twenty-five rats were divided into five groups: normal (N), hyperlipidemic (HL), hyperlipidemic rats treated with simvastatin (HL+SV), hyperlipidemic rats treated with 30 or 90mg 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one per 200g body weight per day (HL+30 or HL+90, respectively). The drugs were administered orally by gavage for 4 weeks.

**Atherogenic index measurement**

Assay kits for serum triglyceride (TG) and high-density lipoprotein (HDL) were purchased from Dyasis® (Holzheim, Germany). The atherogenic index (AI) was calculated using the following equation: AI=log (TG/HDL) [8].

**Gene expression analysis using quantitative polymerase chain reaction (qPCR)**

The cDNAs were synthesized using the iScript cDNA Synthesis kit (Bio-Rad) according to the manufacturer’s protocol. The SsoFast™ Evagreen® Supermix (Bio-Rad) was used for qPCR on an iCycler Model CFX 96 Real-Time System (Bio-Rad). The qPCR reaction was conducted for each gene (*Nrf2* and *GPx*) using the same internal control *Beta actin* gene (Table 1). The program for cDNA amplification was 5 min at 95°C, followed by 40 cycles at 95°C for 60 sec, and 57°C for 60 sec.

**Table 1:** Primer sequences for cDNA amplification

| Gene | Primer sequence (5′-3′) |
|------|-------------------------|
| Nrf2 | F 5′-GCCTTCCTCTGTCCATAGTC-3′<br>R 5′-TGCTCTCATTGCTGTGTTT-3′ |
| GPx  | F 5′-GCTGCTATTGAGATGTCCG-3′<br>R 5′-GAATCTTCTCTGATGCTATC-3′ |
| Beta | F 5′-ACGCTAGTGTGATCCGCAT-3′<br>R 5′-GGCATAGAGGCTTTAGC-3′ |

**Statistical analysis**

The results are expressed as mean ± standard deviation (SD). Differences in atherogenic indices among the groups before and after treatment with 30 or 90mg 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one per 200g body weight per day (HL+30 or HL+90, respectively) were analyzed by one-way ANOVA followed by Games-Howell test. The expression levels of liver *Nrf2* and *GPx* genes after treatment were compared by one-way ANOVA followed by the Games-Howell tests. Paired t-tests were used to analyze the
atherogenic index before and after treatment. Differences were considered significant at \( p<0.05 \).

**RESULTS**

After 4 weeks of daily administration of 30 or 90mg of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one per 200g body weight, serum triglyceride levels decreased significantly \((p<0.05)\). The results are shown in Table 2. As shown in Table 3, HDL levels increased significantly \((p<0.05)\) after administration of 30 or 90 mg of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one per 200g body weight per day for 4 weeks.

Administration of 30 or 90mg of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one per 200g body weight per day for 4 weeks significantly reduced the atherogenic index \((p<0.05)\). The greatest decline was observed in the group treated with 90 mg of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one per 200g body weight (Table 4).

Administration of 30 or 90mg of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one per 200g body weight per day for 4 weeks significantly reduced the relative gene expression of \( Nrf2 \) in rat liver tissue \((p>0.05, \text{Figure 1})\).

Administration of 30 or 90mg of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one per 200g body weight per day for 4 weeks significantly reduced the relative gene expression levels of \( GPx \) in rat liver tissue \((p>0.05, \text{Figure 2})\).

**DISCUSSION**

This study showed that administration of 30 or 90mg of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one per 200g body weight per day for 4 weeks lowered the levels of triglycerides, increased HDL levels, and reduced the atherogenic index \((p<0.05)\). Based on these results, we conclude that 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one has the potential to treat dyslipidemia.

Mallick and Khan [9] reported that sweet oranges \(( \text{Citrus sinensis} \) and grapefruit \(( \text{Citrus paradisi} \) produce antioxidants that have hypolipidemic effects in rats fed with a cholesterol-rich diet. Another study showed that chrysin flavonoid from honey, propolis, and plant extracts exerted

---

**Table 2: Effect of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one on serum triglyceride levels (mg/dL) in a hyperlipidemic rat**

| Group      | Mean (mg/dL) ± SD Before | Mean (mg/dL) ± SD After | Mean difference (95% CI) | \( P \)-value |
|------------|--------------------------|-------------------------|--------------------------|---------------|
| Normal     | 67.47 ± 2.75             | 68.12 ± 2.41            | -0.65 (-1.07; -0.23)     | 0.013         |
| Hyperlipidemc | 135.97 ± 9.49         | 138.05 ± 9.02           | -2.08 (-3.85; -0.30)     | 0.031         |
| HL + SV    | 132.88 ± 5.55            | 79.25 ± 3.04            | 53.63 (43.25; 64.01)     | 0.000         |
| HL + 30    | 126.52 ± 7.86            | 92.78 ± 3.13            | 33.74 (21.85; 45.64)     | 0.001         |
| HL + 90    | 133.05 ± 7.60            | 86.17 ± 3.04            | 46.88 (38.91; 54.85)     | 0.000         |

**Table 3: Effect of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one on HDL levels (mg/dL) in a hyperlipidemic rats**

| Group      | Mean (mg/dL) ± SD Before | Mean (mg/dL) ± SD After | Mean difference (95% CI) \( P \)-value |
|------------|--------------------------|-------------------------|---------------------------------------|
| Normal     | 73.63 ± 2.46             | 75.21 ± 2.92            | -1.58 (-3.03; -0.13) \( p<0.05 \)   |
| Hyperlipidemc | 24.25 ± 2.69          | 23.32 ± 2.86            | 0.93 (0.35; 1.50) \( p<0.05 \)     |
| HL + SV    | 25.48 ± 2.83             | 61.31 ± 3.73            | -35.83 (-42.14; -29.52) \( p<0.05 \) |
| HL + 30    | 27.08 ± 2.04             | 46.79 ± 1.86            | -19.72 (-23.20; -16.23) \( p<0.05 \) |
| HL + 90    | 26.37 ± 3.83             | 55.44 ± 1.85            | -29.07 (-35.24; -22.91) \( p<0.05 \) |

**Table 4: Effect of 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one on atherogenic index in a hyperlipidemic rat**

| Group      | Atherogenic index Before | Atherogenic index After | Mean difference (95% CI) \( P \)-value |
|------------|--------------------------|-------------------------|---------------------------------------|
| Normal     | -0.04 ± 0.023            | -0.04 ± 0.018           | 0.005 (-0.006; 0.016) \( p<0.05 \) |
| Hyperlipidemc | 0.75 ± 0.070           | 0.77 ± 0.070            | -0.024 (-0.036; -0.011) \( p<0.05 \) |
| HL + SV    | 0.72 ± 0.057             | 0.11 ± 0.037            | 0.607 (0.507; 0.707) \( p<0.05 \)   |
| HL + 30    | 0.87 ± 0.030             | 0.30 ± 0.010            | 0.373 (0.340; 0.406) \( p<0.05 \)   |
| HL + 90    | 0.71 ± 0.091             | 0.19 ± 0.003            | 0.515 (0.402; 0.628) \( p<0.05 \)   |

---

_Trop J Pharm Res, June 2019; 18(6): 1175_
antioxidant and hypolipidemic effects on Triton WR-1339–induced hyperlipidemia in female C57BL/6 mice [10]. Zeni et al. [11] reported that black mulberry (Morus nigra) leaf extracts contained abundant polyphenols, particularly chlorogenic acid. Chlorogenic acid had beneficial effects by reducing cholesterol and controlling fatty accumulations in the liver by increasing peroxisome proliferator–activated receptor alpha (PPAR-α) [12].

In the present study, rats with dyslipidemia had higher Nrf2 expression levels than normal rats, and treatment with 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one isolated from mahogany (Swietenia macrophylla King) seeds reduced the Nrf2 expression levels. These results suggest that 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one has antioxidant properties that reduce dyslipidemia-induced oxidative stress. Polyphenolic compounds and antioxidant activity also were detected in extracts of white (Morus alba) and black (Morus nigra) mulberry leaf [13-15].

GPx is localized in the cytoplasm, in the mitochondrial matrix, and in insoluble forms associated with membranes involved in the neutralization of lipid hydroperoxides [16]. The GPx function is responsible for lowering hydrogen peroxide (H₂O₂) levels and converting lipoxygenases and organic hydroperoxides into suitable hydroxylation compounds, which are less reactive. Quercetin has in vivo antioxidant properties, and quercetin treatment increases hepatic GPx expression in older rats [17]. Research by Martin et al [18] showed that cocoa polyphenolic extract was an effective inducer of GPx. These reports are consistent with the study of Phachonpai et al [19], which reported that quercetin added to rat diet significantly increased the superoxide dismutase (SOD), catalase (CAT), and GPx activities [19,20].

CONCLUSION

The results of this study indicate that 7-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4-one lowers the atherogenic index and expression levels of Nrf2 and GPx genes in hyperlipidemic rats, and there may be suitable for management of hyperlipidemia but further investigations are required to ascertain this.

DECLARATIONS

Acknowledgement

This study was supported by the Community Funds from Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Conflict of interest

No conflict of interest is associated with this study.

Contribution of authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors”. All authors read and approved the manuscript for publication.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/real), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Liu C, Lin JD. PGC-1 Coactivators in the control of energy metabolism. Acta Biochim Biophys Sin 2011; 43(4): 248-257.

2. Kløvseth CD, Reisman SA. Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver. Toxicol. Appl. Pharmacol 2010; 244(1): 57–65.

3. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol.Toxicol 2013; 53: 401–426

4. Itoh K, Ishii T, Wakabayashi N, Yamamoto M. Regulatory mechanisms of cellular response to oxidative stress. Free Radic Res 1999; 31: 319–324.

5. Danielli NM, Trevisan R, Mello DF, Fischer K, Deconto VS, da Silva Acosta D, Bianchini A, Bainy ACD, Dafre VS, da Silva Acosta D, Bianchini A, Bainy ACD, Dafre A. Upregulating Nrf2-dependent antioxidant defenses in Pacific oysters Crassostrea gigas: Investigating the Nrf2/Keap1 pathway in bivalves. Comp Biochem Physiol C Toxicol Pharmacol. 2017; Part C 195 :16–26

6. Prasetyastuti, Sunarti, Sadewa AH, Mustofa. Effect of 7-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chroman-4-one (Swietenia Macrophylla KING seed) on Retinol Binding Protein-4 and Phosphoenolpyruvate Carboxykinase gene Expression in Type 2 Diabetic rats. Rom J Diabetes Nutr Metab Dis 2016; 23(3): 255-265.

7. World Health Organization. Declaration of Helsinki. Br Med J 1996; 313(7070): 1448-1449.

8. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL). Clin Biochem 2001; 34(7): 583-588.

9. Mallick N, Khan RA. Antihyperlipidemic effects of Citrus sinensis, Citrus paradisi, and their combinations. J Pharm Bioallied Sci 2016; 8(2): 112–118.

10. Zarzecki MS, Araujo SM, Bortolotto VC, De Paula MT, Jesse CR, Prigol M. Hypolipidemic action of chrysin on Triton WR-1339- induced hyperlipidemia in female C57BL/6 mice. Toxicol Rep 2014; 1: 200-208

11. Zeni ALB, Moreira TD, Dalmagro AP, Camargo A, Bini LA, Simonatto EL, Scharf DR. Evaluation of phenolic compounds and lipid-lowering effect of Morus nigra leaves extract. An Acad Bras Cien 2017; 89(4): 2805-2815

12. Wan CW, Wong CN, Pin WK, Wong MH, Kwok CY, Chan RY, Yu PH, Chan SY. Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-α in hypercholesterolemic rats induced with a high-cholesterol diet. Phytother Res 2013; 27: 545-551.

13. Sánchez-Salcedo EM, Mena P, García-Viguera C, Hernández F, Martínez JJ. (Poly) phenolic compounds and antioxidant activity of white (Morus alba) and black (Morus nigra) mulberry leaves Their potential for new products rich in phytochemicals. J Funct Foods 2015; 18: 1039-1046.

14. Mahi TH, Qadir MI, Khan YH, Ali M. Hepatoprotective activity of aqueous methanolic extract of Morus nigra against paracetamol-induced hepatotoxicity in mice. Bangladesh J Pharmacol 2014; 9(1) 60-66.

15. Araújo CM, Lúcio KP, Silva ME, Isoldi MC, de Souza GH, Brandão GC, Schultz R, Costa DC. Morus nigra leaf extract improves glycemic response and redox in the liver of diabetic rats. Food Funct 2015; 6: 3490-3499.

16. Martinez-Hervas S, Fandos M, Real JT, Espinosa O, Chaves FJ, Saez GT, Salvador A, Cerdá C, Carmen R, Ascaso JF. Insulin resistance and oxidative stress in familial combined hyperlipidemia. Atherosclerosis. 2008; 199(2): 384-389.

17. Nassef N, Louka M, Habib H. Quercetin Flavonoid Has In Vivo Antioxidant Properties By Increasing Hepatic Expression of Gpx and Hepatic Gpx Enzyme Activity In Old Rats [Abstract]. Physiol 2013; 27(1). Supplement.

18. Martin MA, Serrano ABG, Sonia Ramos S, Pulido M, Bravo L, Goya L. Cocoa flavonoids up-regulate antioxidant enzyme activity via the ERK1/2 pathway to protect against oxidative stress-induced apoptosis in HepG2 cells. J Nutr Biochem 2010; 21 :196–205.

19. Phachonpai W, Wattanathom J, Muchimapura S, TongUn T, Preechagoon D. Neuroprotective effect of quercetin encapsulated liposomes: A novel therapeutic strategy against Alzheimer’s disease. Am J Appl Sci 2010; 7(4): 480-485.

20. Sriraksa N, Wattanathom J, Muchimapura S, Tiamkao S, Brown K, Chaisiwamongkol K. Cognitive enhancing effect of quercetin in a rat model of Parkinson’s disease induced by 6-hydroxydopamine. Evid Based Complement Alternat Med 2012; 2012: 1-9.